Last reviewed · How we verify
NCT04705519
Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
Phase 2 trial testing Nab-paclitaxel Combined With Bevacizumab in Neuroendocrine Carcinoma in 79 participants. Completed in 30 September 2024.
30 September 2024
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 79 |
| Start date | 5 January 2021 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Nab-paclitaxel Combined With Bevacizumab — full drug profile →
Conditions studied
- Neuroendocrine Carcinoma — all drugs for Neuroendocrine Carcinoma →
Sponsor
Peking University
Who can join
18 and older, any sex, with Neuroendocrine Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, phase II study evaluating efficacy and safety of Nab-paclitaxel Combined With Bevacizumab for unresectable Recurrent or metastatic extrapulmonary neuroendocrine carcinoma.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.
Frizziero M, Kilgour E, Simpson KL, Rothwell DG, et al · · 2022 · cited 30× · PMID 35091446 · DOI 10.1158/1078-0432.ccr-21-3058 -
Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.
Ooki A, Osumi H, Fukuda K, Yamaguchi K. · · 2023 · cited 16× · PMID 37422534 · DOI 10.1007/s10555-023-10121-2 -
Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review.
Robinson MD, Livesey D, Hubner RA, Valle JW, et al · · 2023 · cited 8× · PMID 36872945 · DOI 10.1177/17588359231156870 -
The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms.
Xu S, Ye C, Chen R, Li Q, et al · · 2022 · cited 6× · PMID 35740577 · DOI 10.3390/cancers14122911 -
Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study.
Zhang P, Li S, Jia R, Hao J, et al · · 2025 · cited 3× · PMID 41209655 · DOI 10.1016/j.eclinm.2025.103598
Verify or expand the search:
- PubMed search for NCT04705519
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neuroendocrine Carcinoma
Currently open trials in the same condition.
- NCT06937905 — Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic P · Phase 3 · recruiting
- NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting
- NCT06577987 — Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies · Phase 1 · recruiting
- NCT06242119 — Clinical Application of the J-PET Scanner Prototype · recruiting
- NCT04524208 — A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 · Phase 2 · active not recruiting
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04705519 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 14 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04705519.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing